These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29912794)

  • 1. Intraindividual and Interindividual Variability of Olanzapine Trough Concentrations in Patients Treated With the Long-Acting Injectable Formulation.
    Baldelli S; Mauri MC; Di Pace C; Paletta S; Reggiori A; Rovera C; Clementi E; Cattaneo D
    J Clin Psychopharmacol; 2018 Aug; 38(4):365-369. PubMed ID: 29912794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
    Mitchell M; Kothare P; Bergstrom R; Zhao F; Jen KY; Walker D; Johnson J; McDonnell D
    Clin Ther; 2013 Dec; 35(12):1890-908. PubMed ID: 24184052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.
    Heres S; Kraemer S; Bergstrom RF; Detke HC
    Int Clin Psychopharmacol; 2014 Nov; 29(6):299-312. PubMed ID: 24815672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.
    Tveito M; Smith RL; Høiseth G; Molden E
    J Clin Psychopharmacol; 2019; 39(6):561-566. PubMed ID: 31688390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.
    Tveito M; Smith RL; Molden E; Haslemo T; Refsum H; Hartberg C; Correll CU; Høiseth G
    J Clin Psychopharmacol; 2018 Dec; 38(6):570-576. PubMed ID: 30300295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.
    Pietrini F; Spadafora M; Tatini L; Talamba GA; Andrisano C; Boncompagni G; Manetti M; Ricca V; Ballerini A
    Eur Psychiatry; 2016 Sep; 37():35-42. PubMed ID: 27442981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.
    Detke HC; Zhao F; Garhyan P; Carlson J; McDonnell D
    Int Clin Psychopharmacol; 2011 Jan; 26(1):35-42. PubMed ID: 20948432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large intraindividual variability of olanzapine serum concentrations in adolescent patients.
    Bachmann CJ; Haberhausen M; Heinzel-Gutenbrunner M; Remschmidt H; Theisen FM
    Ther Drug Monit; 2008 Feb; 30(1):108-12. PubMed ID: 18223472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.
    Detke HC; Weiden PJ; Llorca PM; Choukour M; Watson SB; Brunner E; Ascher-Svanum H
    J Clin Psychopharmacol; 2014 Aug; 34(4):426-34. PubMed ID: 24781441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.
    Mauri MC; Maffini M; Di Pace C; Reggiori A; Paletta S; Moliterno D; Rovera C; Altamura CA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):99-105. PubMed ID: 25547438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.
    McDonnell DP; Detke HC; Bergstrom RF; Kothare P; Johnson J; Stickelmeyer M; Sanchez-Felix MV; Sorsaburu S; Mitchell MI
    BMC Psychiatry; 2010 Jun; 10():45. PubMed ID: 20537130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients.
    Tveito M; Smith RL; Molden E; Høiseth G
    Eur J Clin Pharmacol; 2021 Feb; 77(2):215-221. PubMed ID: 33000414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
    Hill AL; Sun B; McDonnell DP
    Clin Schizophr Relat Psychoses; 2014 Jan; 7(4):216-22. PubMed ID: 23428782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.
    McDonnell DP; Kryzhanovskaya LA; Zhao F; Detke HC; Feldman PD
    Hum Psychopharmacol; 2011 Aug; 26(6):422-33. PubMed ID: 21823172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.
    Italiano D; Bruno A; Santoro V; Lanza G; Muscatello MR; Zoccali R; Spina E
    Ther Drug Monit; 2015 Dec; 37(6):827-30. PubMed ID: 25830930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
    Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
    Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
    Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
    Lobo ED; Robertson-Plouch C; Quinlan T; Hong Q; Bergstrom RF
    Paediatr Drugs; 2010 Jun; 12(3):201-11. PubMed ID: 20297865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine.
    Korell J; Green B; Rae A; Remmerie B; Vermeulen A
    Eur J Clin Pharmacol; 2018 May; 74(5):593-599. PubMed ID: 29392351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
    Mamo D; Kapur S; Keshavan M; Laruelle M; Taylor CC; Kothare PA; Barsoum P; McDonnell D
    Neuropsychopharmacology; 2008 Jan; 33(2):298-304. PubMed ID: 17443131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.